Dr. Xiang is an accomplished drug hunter with over 20 years experience in discovery and development of therapeutics for oncology, autoimmune and metabolic disease. Dr. Xiang experience spans multiple therapeutic modalities including small molecules, antibody-drug conjugates as well as bifunctional protein degraders (PROTACs). Dr. Xiang led preclinical and development program teams that led to multiple clinical products including three commercial products. Prior to founding Polymed, Dr. Xiang led the research and development team at Suzhou Kintor (HKG:9939) as Chief Technology Officer. Dr. Xiang also led Chemistry at ChemPartners as the Vice President for 6 years. Dr. Xiang started his career at Wyeth Pharmaceuticals (now part of Pfizer Inc), where he led a number of preclinical drug discovery teams during his 13 yr career. Dr. Xiang has received numerous awards such as Monsanto Outstanding Research Award, Abbott Excellent Organic Research Award, Wyeth Clinical Candidate Award and 2017 Shanghai Small Business Innovation Award. He published 63 publications in top-tier journals and 18 Issued patents. In addition to his scientific acumen, Dr. Xiang is a proven goal-oriented business leader and has developed business strategy, raised funds for early stage ventures and executed on strategic collaborations with large pharma, biotech, venture and academic partners.

Dr. He Zhou: Senior Vice President and Chief Operation Officer Dr, Zhou is a seasoned industry veteran with 20+ years of experience in preclinical/clinical drug development, and management. Prior to joining Polymed, Dr. Zhou served as Head of Oncology Pharmacology at Momenta Pharmaceuticals (a wholly-owned subsidiary of Johnson & Johnson), Head of Oncology Pharmacology and Executive Director at Shanghai ChemPartner, Senior Director in Clinical Biomarker at BeiGene, China General Manager and VP at HiFiBiO Therapeutics, Head of Research and VP at Beijing Migrasome Therapeutics. She led multiple projects, including 5 (3 antibodies, a small molecule, and a carbohydrate) as a core member through screening to successful IND filing, with 10+ drug candidates entering clinical trials, 3 approved and marketed. With her medical training, she also participated in multiple Phase I-III clinical trials in US and China, led and completed 1 Phase I clinical trial in China. Dr. Zhou received her B.S. in Medicine and a M.S. in Immunology from Peking University Health Science Center (formerly Beijing Medical University) and her Ph.D. in Immunology from University of Mississippi Medical Center. She completed her postdoctoral training in Immuno-Oncology in Dr. Ralph Reisfeld’s laboratory at The Scripps Research Institute. She has published 40 research articles in high-impact journals such as Cancer Cell and Nature Communications, and 6 issued patents.